Applications of privacy-enhancing technology to data sharing at a global pharmaceutical company
Janssen has been at the forefront of the recent pharmaceutical industry trend towards more transparency and sharing of clinical trials data, committing early on to make its data available for both internal and external innovation. Janssen is also committed to protecting patient privacy and giving individuals a voice on how their data is used and disclosed. This paper outlines Janssen’s data-sharing initiatives and describes how it is using leading-edge privacy-enhancing technologies (PETs) to mitigate privacy risks and find the right balance between innovation and privacy.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: Head of Clinical Data Standards & Transparency, The Janssen Pharmaceutical Companies of Johnson & Johnson
Publication date: June 1, 2020
More about this publication?
- Journal of Data Protection & Privacy publishes in-depth, peer-reviewed articles, case studies and applied research on all aspects of data protection, information security and privacy issues across the European Union and other jurisdictions, in the wake of the new EU General Data Protection Regulation (GDPR) and the biggest change in data protection and privacy for two decades.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites